Newborn Screening Market Estimated to Exceed US$ 1.3 Billion by 2026 | CAGR: 12.4%: Coherent Market Insights
Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-pdf/2192
The global newborn screening market, by Product Type (Assay Kits, Hearing Screening Devices, Mass Spectrometer, and Pulse Oximetry), By Application (Blood Spot Disease, Critical Congenital Cardiac Disease, Maple Syrup Urine Disease, Hearing Disability, Sickle Cell Disease, and Thyroid Disorder), by Test (Blood Test, Cardiac Test, Hearing Test, and Urine Test), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 561.5 million in 2018 and is projected to exhibit a CAGR of 12.4% over the forecast period (2018-2026).
Newborn screening tests look for developmental, metabolic, and genetic disorders in infants. A majority of these illnesses are very rare, they can be treated with early diagnosis. Newborn screening involves tests of around 30 conditions and illnesses. Increasing awareness among parents for disease screening is a major factor driving newborn screening market growth. In addition, various government and non-government organizations are actively focused on offering better fetal and maternal care.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/newborn-screening-market-to-surpass-us-13-billion-by-2026-1136
In June 2018, the American Society of Hematology (ASH) led a campaign to fight sickle cell disease in Africa and urged governments in the region to invest in newborn screening of the disease. A multitude of treatments, new biomarkers and technologies are expected to enable various diseases to be considered as potential candidates to be included in New Born Screening (NBS) programs. For instance, new treatments such as Hematopoietic Stem Cell Transplant (HSCT), Enzyme Replacement Therapy (ERT), and gene therapy, as well as new pharmacological drugs, have allowed autoimmune diseases to be regarded as potential candidates for several NBS programs.
The key market players are majorly focused on the development of novel test kits and devices in order to diagnose more diseases or disorders at birth. In February 2018, Sema4 launched Sema4 Natalis, a supplemental newborn screening test designed to detect 193 childhood-onset diseases or disorders. Also, various governments around the world are supporting manufacturers to develop new screening tests by relaxing regulations for manufacturing and marketing products.
In February 2017, the U.S. FDA approved marketing of the Seeker System for the screening of four, rare Lysosomal Storage Disorders (LSDs) in newborns. The system is designed to detect Fabry, Gaucher, Mucopolysaccharidosis Type I (MPS I), and Pompe.
Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2192
Key Market Takeaways:
- According to the National Institute of Health, NBS programs across the U.S. are known to screen around four million infants annually. This public health program detects treatable disorders in newborns, allowing treatment to begin often before symptoms or permanent problems occur.
- Among the various product types, the assay kits segment is projected to account for a major revenue share in 2018, owing to the escalating number of blood tests being conducted worldwide.
- The notable players operating in the global newborn screening market include Agilent Technologies, AB SCIEX, Bio-Rad Laboratories, Covidien PLC, GE Life Sciences, Masimo Corporation, Natus Medical Inc., PerkinElmer Inc., and ZenTech S.A.
Have a Look at Related Research Insights:
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.
Editor Details
-
Company:
- CDN Newswire
